Introduction
============

While most of us experience acute low back pain at some point in our lives, some will develop chronic low back pain (cLBP), with persistent pain lasting more than 6 months. An estimated one in five adults is currently in chronic pain, with cLBP being the most common ([@B7]) and the world's leading cause of disability ([@B27]; [@B33]). It is believed that maladaptive cognitions and emotional responses to pain are important factors for developing and maintaining chronic pain, as described by the fear avoidance model ([@B88], [@B85]). This model describes how, if immediate pain control is prioritized, pain-catastrophizing and pain-related fear may lead to pain-hypervigilance and avoidance behavior, and in turn increased functional disabilities. This then may amplify the pain experience and paradoxically increases pain-related fear, creating a vicious cycle. A subgroup of patients with cLBP indeed shows pain-related fears, including fear of movement and/or re-injury ([@B13]; [@B90]; [@B9]; [@B79]; [@B8]; [@B33]). In fact, pain-related fear is more closely linked to disability than pain intensity ([@B13]; [@B96]).

To specifically target pain-related fears in clinical settings, Exposure *in vivo* (EXP) was developed. EXP is a cognitive-behavioral treatment based on experimental work showing that exposure to fearful activities and movements, rather than avoiding them, challenges catastrophic pain beliefs and can result in the extinction of fears and maladaptive responses ([@B87]; [@B55]). In EXP, movements and activities that are perceived as threatening and fearful are first identified using the pictorial tool The Photographic Series of Daily Activities (PHODA) ([@B45]). Then, the patient is repeatedly exposed to these feared movements and activities, while behavioral experiments are performed to challenge catastrophic expectations and interpretations regarding these movements, activities, and/or sensations. EXP has been applied as treatment for patients with chronic pain and elevated pain-related fear in a variety of settings and different pain conditions, including, but not limited to, non-specific cLBP. Ubiquitously, EXP has been successful in reducing pain-related fears and pain-related disability as compared to no treatment and at least as successful, if not more successful, in comparison to other treatments that are proven effective ([@B86]; [@B4]; [@B15], [@B14], [@B16]; [@B46]; [@B95]; [@B17]; [@B42]; [@B48]; [@B28]).

It would be expected that EXP specifically impacts the neural circuitry involved in pain-related fear and fear extinction learning. Studies examining pain-related fear have identified altered neural responses in patients with cLBP to viewing and imagining activities/movements associated with pain ([@B77]; [@B54], [@B53]) -- including increased recruitment of the insula, anterior cingulate cortex (ACC), amygdala, orbitofrontal cortex, striatum (i.e., regions involved in attentional/perceptual as well as affective/reappraisive aspects of pain), and altered crosstalk with the periaqueductal gray (PAG; involved in top-down pain modulation). For fear conditioning and extinction, experimental studies identified a core neural network, including the amygdala, insula, and ACC ([@B67]; [@B25], [@B24]). Only few imaging studies investigated fear learning and extinction in the context of pain ([@B38]; [@B41]; [@B36]), reporting altered neural responses in patients, including in the prefrontal cortex (PFC), ACC, insula, amygdala, hippocampus, PAG and thalamus. Further, results of clinical studies in chronic pain investigating treatment-induced functional brain changes show some overlap with neural changes related to pain-related fear and experimental fear extinction (e.g., implicating the amygdala, mPFC, and PAG) ([@B1]; [@B3]; [@B20]; [@B71]). The majority of treatment studies focused on intrinsic brain activity, i.e., in rest and without a specific task ([@B59]; [@B31]; [@B6]). The effects of EXP specifically have also only been investigated using resting-state fMRI ([@B97]), showing that patients with post-traumatic stress disorder showed enhanced post-treatment resting-state functional connectivity between the amygdala, orbitofrontal cortex, hippocampus and the medial PFC. To date, there have been no studies investigating how (EXP) treatment modulates the circuitry underlying pain-related fear in chronic pain.

Therefore, the current longitudinal fMRI study tested the hypothesis that EXP acts upon the neural circuitry involved in pain-related fear, using a task designed to evoke pain-related fear. We compared patients with cLBP with pain-free volunteers pre- and post-EXP treatment; the cLBP group was also examined 6 months after end of treatment. We evaluated group differences and treatment effects in evoked brain activation. Also, more exploratively, we used (changes in) fear ratings to identify neural correlates specific to (reductions in) pain-related fear. A whole-brain approach was adopted in combination with analyses in *a priori* defined regions of interest (ROIs) that were considered to be of particular interest due to their involvement in pain-related fear and experimental extinction learning (i.e., amygdala, hippocampus, mPFC, PAG) and/or pain chronification (i.e., mPFC, NAc). We expected (I) pre-treatment group differences in neural circuitry recruited by stimuli evoking pain-related fear, correlated to fear ratings as well as pain-related outcomes in patients; (II) patient-specific pre- to post-treatment changes in regions showing pre-treatment group differences, as well as in other brain regions associated with chronic pain and with extinction (i.e., amygdala, hippocampus, mPFC, NAc, PAG); (III) pre- to post-treatment changes associated with changes in fear and persisting at 6 months follow-up.

Materials and Methods
=====================

Overall Study Procedure
-----------------------

This study presents data of a larger study investigating effects of EXP on chronic pain, "BrainEXPain". BrainEXPain was approved by the Medical Ethical Committee of Maastricht University Hospital/Maastricht University (MUMC+/UM), and the protocol is registered at [ClinicalTrials.gov](https://clinicaltrials.gov) \[NCT02347579\]. Patient recruitment was done via the department of Rehabilitation Medicine at MUMC+/Adelante rehabilitation center where patients were seen for consultation. If patients were found motivated for rehabilitation treatment and eligible for the multi-disciplinary pain screening program, they were invited by the physiatrist for the study. Recruitment was open between January 2015 and August 2017.

Participants were then contacted by the research team and were screened for in- and exclusion criteria. Informed consent was obtained at study enrollment. Prior to scanning, all participants filled in questionnaires online (Qualtrics, Provo, United States^[1](#footnote1){ref-type="fn"}^). The first study visit was scheduled prior to any (information on) treatment (i.e., baseline or pre-EXP). Afterward, patients underwent a multi-disciplinary pain screening and pain education, and started the exposure sessions (if eligible for treatment) -- which were all part of standard care. At the end of treatment, patients underwent a post-EXP and a follow-up study visit (6 months after end of treatment; FU-EXP). Healthy controls participated in two study visits, with the time in between these visits matching the patients' pre- to post-EXP. Participants received €15 per study visit and travel reimbursement for their participation.

Participants
------------

Inclusion criteria for patients were age between 18 and 65 years, stable medication,^[2](#footnote2){ref-type="fn"}^ experience of non-specific LBP \> 6 months, and no other diagnosis explaining the symptoms. Exclusion criteria were claustrophobia, MRI incompatibility (e.g., pacemaker, pregnancy), and severe psychopathology (Symptom Check List-90). Of the 35 patients with cLBP invited by the physiatrist over the 2.5 years inclusion period, 23 patients with cLBP were included in BrainEXPain (8 patients were not interested in participating, 4 patients were MRI incompatible). Of these, three patients dropped out prior to or during the measurement (due to claustrophobia); of two patients the data analyzed here was not acquired due to technical error; three patients were excluded due to extensive motion (see Data Analysis); and one patient was excluded due to lack of any vision-related (occipital) activity (see Data Analysis). The final sample for this study therefore consisted of 14 patients ([Table 1](#T1){ref-type="table"}). Post-EXP data is available for 10 patients (three did not start EXP, one became MRI incompatible), and FU-EXP data is available for 9 patients (1 was lost to follow-up due to unrelated medical issues).

###### 

Demographics of the final sample.

  ---------------------------------------------------------------------------------------------------------------
                  **Patients with cLBP**   **Pain-free volunteers**   **Statistics for group**
  --------------- ------------------------ -------------------------- -------------------------------------------
  Sample size     *n* = 14                 *n* = 14                   n.a.

  Age (years)     42.4 (11.6)              41.7 (12.5)                *F*~(1,26)~ = 0.02, *p* = 0.89

  Sex             11 males\                10 males\                  *X*^2^~(1,*n*\ =\ 28)~ = 0.19, *p* = 0.66
                  3 females                4 females                  

  Handedness      13 right-handed\         14 right-handed\           *X*^2^~(1,*n*\ =\ 28)~ = 1.04, *p* = 0.31
                  0 left-handed\           0 left-handed\             
                  1 ambidextrous           0 ambidextrous             

  Pain duration   6--12 months: *n* = 1\   n.a.                       n.a.
                  1--2 years: *n* = 3\                                
                  2--5 years: *n* = 8\                                
                  \>5 years: *n* = 2                                  
  ---------------------------------------------------------------------------------------------------------------

n.a., not applicable.

The patient group was compared to a sample of 14 pain-free healthy volunteers, matched for age, sex and handedness on cohort-level. To match the patient group, 10 controls underwent a second study visit. Controls were recruited through local advertisements. Additional exclusion criteria were: history of a chronic pain syndrome, and seeking treatment for a pain condition in the last 6 months.

Exposure *in vivo* Treatment
----------------------------

Within MUMC+/Adelante, EXP is standard care for patients with cLBP presenting with elevated pain-related fear. No additional restrictions or requirements for EXP were set by BrainEXPain. EXP specifically aims to reduce disability by challenging erroneous interpretations and expectancies about pain (e.g., that pain always indicates harm or that activities cause harm). A detailed description of the exposure-protocol for pain-related fear can be found in [@B89]. In brief, EXP always started with identifying movements/activities that are perceived as threatening and fearful, education about treatment rationale and that harm or pain does not mean additional injury (i.e., by discussing MR images of the spine by the treating physiatrist). EXP then continued with repeated exposure to feared movements, activities and/or sensations combined with behavioral experiments to challenge catastrophic interpretations by creating violations of expectancies. Patients were furthermore instructed to keep performing the movements and/or activities they performed during their sessions. EXP typically consists of 16 sessions (although it could be shortened to 8 or extended to 20, per clinicians' decision), which are guided by a psychologist and either a physical or an occupational therapist. To identify movements and activities that are perceived as threatening and fearful, EXP utilizes The Photographic Series of Daily Activities (PHODA) for the low back ([@B45]). The PHODA consists of photographs depicting back-related movements and activities that are rated based on their perceived harmfulness. See [Table 2](#T2){ref-type="table"} for more participant and EXP-related characteristics.

###### 

Information about EXP and the repeated measures.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                **Patients with cLBP**          **Pain-free volunteers**   **Statistics for group**
  ------------------------------------------------------------- ------------------------------- -------------------------- ---------------------------------------------
  Sample size                                                   *n* = 10 (*n* = 9 for FU-EXP)   n = 10                     n.a.

  Age (years)                                                   40.2 (11.3)                     39.6 (12.2)                *F*~(1,18)~ = 0.01, *p* = 0.91

  Sex                                                           9 males\                        8 males\                   *X*^2^~(1,\ *n*\ =\ 20)~ = 0.39, *p* = 0.53
                                                                1 female                        2 females                  

  Pain duration                                                 6--12 months: *n* = 1\          n.a.                       n.a.
                                                                1--2 years: *n* = 2\                                       
                                                                2--5 years: *n* = 5\                                       
                                                                \>5 years: *n* = 2                                         

  EXP treatment duration (days)                                 45.0 (15.9)                     n.a.                       n.a.

  Time between pre-EXP session and start EXP treatment (days)   29.3 (12.2)                     n.a.                       n.a.

  Time between pre-EXP and post-EXP session (days)              96.1 (42.1)                     92.3 (33.5)                *F*~(1,18)~ = 0.05, *p* = 0.83

  Time between post-EXP and FU-EXP session (days)               186.4 (9.6)                     n.a.                       n.a.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

n.a., not applicable.

Assessment of Pain-Related Aspects and Performance Levels
---------------------------------------------------------

At all time-points we assessed: pain intensity using a 0--10 visual analog scale anchored with "no pain at all" and "worst pain imaginable"; pain-related fear using the PHODA short electronic version for low back ([@B45]), and Tampa Scale for Kinesiophobia (TSK; [@B39]; [@B87]), Pain Catastrophizing Scale (PCS; [@B75]; [@B13]), Pain Disability Index (PDI; [@B76]; [@B72]), Physical Activity Rating Scale combined with the Perceived Activity Decline (PARS/PAD; [@B84]; [@B83]) questionnaire. Only assessed at baseline as trait measures were: Fear of Pain Questionnaire (PFQ; [@B51]; [@B82]) and State Trait Anxiety Inventory (STAI-Y2; [@B81]; [@B74]). In addition, all participants underwent performance testing during all study visits to assess functioning. In the *2 min walking test*, participants walked for 2 min on a standardized track and the covered distance was measured in meters. During *staircase walking*, participants walked a complete staircase (up and down), after which the average time per step was calculated.

Picture Imagination Task
------------------------

In the scanner, the participants were presented with visual stimuli, associated with one of three categories: rest (derived from a web-search -- REST), movements and activities perceived as fearful for patients specifically (derived from the extended version of the PHODA, not used in pain assessment and/or treatment -- MOVEMENT), or pictures implying bodily damage that may be perceived as fearful in general (derived from IAPS ([@B43]) and a web-search -- MEDICAL). Backgrounds were removed to make the physical properties as similar as possible.

Participants were instructed to carefully look at the pictures and imagine that they were the person in the picture (carrying out the movement or activity, if applicable). After a short delay (see [Figure 1](#F1){ref-type="fig"} for details), participants were asked to rate how they would feel if they were the person on the picture (indirect assessment of fear). Ratings were done by pressing a button that moved a cursor on a horizontal line presented on the screen (later converted to 0--10 scores). In total, there were 21 trials (7 of each category). Stimuli were presented using Presentation Software (Neurobehavioral Systems Inc.), and were synchronized with MR data acquisition. The total task had a duration of approximately 8 min. The picture imagination task was always performed second, after a resting-state run. The total duration of the scan was approximately 75--90 min (data from other runs will be described elsewhere).

![Schematic overview of the design of the picture imagination task, showing the elements plus corresponding timing and a zoom into one example trial; TR, repetition time; ISI, inter-stimulus time; ITI, inter-trial time.](fnins-13-00970-g001){#F1}

MRI Acquisition
---------------

MRI data were collected using a 3 Tesla whole body MRI scanner (Philips Gyroscan Achieva TX) using a 32-channel head coil, at the department of Radiology at MUMC+.

For the functional images, a T2^∗^-weighted standard echo-planar imaging (EPI) sequence was used to acquire 40 axial slices (3 mm isotropic) covering the entire cortical volume, using the following parameters: repetition time (TR) = 2000 ms, echo time (TE) = 25 ms, flip angle = 75°, matrix size = 120 × 240, SENSE factor = 2. In total, 225 functional volumes were collected, of which the first two volumes were dummy volumes that were discarded from subsequent analysis to avoid T1 saturation effects.

T1-weighted anatomical images were acquired using a 3D turbo field echo (TFE) sequence with the following parameters: 170 slices, 1 mm isotropic, TR = 8.1 ms, TE = 3.7 ms, flip angle = 8°, matrix size = 240 × 240.

Data Analysis
-------------

### Assessment of Pain-Related Outcomes

Questionnaire and performance test data were analyzed using SPSS (version 24). A general linear model (GLM) with Group (patients, controls) as between-subjects (BS) factor was used to examine group differences pre-EXP, as well as post-EXP. In addition, a repeated measures (rmGLM) with Time \[pre-EXP, post-EXP, (FU-EXP)\] as a within-subjects (WS) factor was used to investigate changes over time.

### Behavioral Data: Picture Imagination Task

Group comparisons in in-scanner fear ratings, focusing on MOVEMENT pictures, were evaluated using a rmGLM with Group (patients, controls) as BS factor and Picture Number (7 different Pictures per Category) as WS factor. In addition, the WS factor Time \[pre-EXP, post-EXP, (FU-EXP)\] was added in a separate analysis.

### MRI Data: Pre-processing

MRI data analysis was performed using BrainVoyager 3.6 (Brain Innovation, Maastricht, the Netherlands). Pre-processing of the functional data included slice scan time correction, 3D head motion correction, linear trend removal, high-pass filtering (5 cycles per run; corresponding to 0.1 Hz), and spatial smoothing \[4 mm using a full-width at half-maximum Gaussian kernel (FWHM)\]. Data was then co-registered to the corresponding anatomical image, and normalized to MNI space. The three pictures categories (REST, MOVEMENT, and MEDICAL) plus the delay prior to the rating (i.e., in total 4--8 s) were used as predictors, convolved with the hemodynamic response function (HRF). Additional information on denoising procedures can be found in [Supplementary Information](#DS1){ref-type="supplementary-material"}.

### MRI Data Analysis: Masking

Whole-brain analyses were run within a mask that excluded the white matter and cerebral spinal fluid, based on the Harvard-Oxford atlases (probability threshold 0.25) ([@B22]; [@B19]; [@B50]; [@B30]). To specifically test our hypotheses in brain regions that play important roles in chronic pain and/or fear extinction, additional analyses were run within predefined region-of -interest (ROI) masks. ROIs were defined in bilateral medial frontal cortex (mPFC), bilateral amygdala, bilateral nucleus accumbens (NAc), bilateral hippocampus based on the Harvard-Oxford subcortical atlas (probability threshold 0.25). A ROI corresponding to bilateral PAG was defined by dilating spheres around coordinates from [@B47] \[*x* = 1, *y* = --29, *z* = --10 (volume = 1612 mm^3^, diameter ∼14.5 mm)\]. In these ROI masks, FDR correction \[*q*(FDR) \< 0.05\] and minimum cluster size of 4 voxels (108 mm^3^) was used for statistical thresholding.

### MRI Data: Group Differences and Treatment Effects

To compare blood-oxygen-level dependent (BOLD) responses across Groups and Times, a univariate random-effects (RFX) analysis with separate subject predictors was run at the first level, after which this data was fed into a second-level RFX analysis where group maps could be estimated and contrasted. FDR correction \[*q*(FDR) \< 0.05\] was used for map creation. In the whole-brain analysis, an initial threshold of *p* \< 0.001 was used for contrasts across Groups and Times, after which cluster-size thresholding was performed using MonteCarlo simulations (*n* = 1000) to correct maps at the level of alpha 0.05. The main contrast of interest was MOVEMENT vs. baseline, plus effects of Group and Time herein, as this condition was designed to elicit pain-related fear specifically in the patient group.

### MRI Data: Correlations With (Changes in) Pain-Related Outcome Measures and Changes in Fear

Two types of correlation analyses were performed. From regions in which significant Group and Time differences were observed, betas were extracted in order to perform correlation analyses with measures of pain-related outcomes. An additional, explorative, analysis for the patients was to examine correlations between changes in fear ratings and changes in neural activation patterns at a whole-brain level. For this, we used the percentage of change in fear ratings for MOVEMENT pictures (at post- and FU-EXP compared to pre-EXP), and took a less conservative initial cluster-defining threshold of *p* \< 0.005 for the cluster-size thresholding.

Results
=======

Pre-treatment (Pre-EXP) Data
----------------------------

### Patients Show High Levels of Fear, Pain, and Disability Pre-EXP

Pre-treatment, patients reported significantly higher levels of pain, pain-related fear, catastrophizing and disability compared to controls ([Table 3](#T3){ref-type="table"}). Groups furthermore differed in trait anxiety, but not in trait fear of pain. Also, patients reported significantly lower levels of physical activity and higher levels of perceived activity decline compared to controls. Lab-assessed performance tests confirmed this: patients covered significantly less distance within 2 min walking, and needed more time to walk stairs, compared to controls.

###### 

Self-reported measures and performance tasks at baseline (pre-EXP).

                                                              **Patients with cLBP Mean (SD)**   **Pain-free volunteers Mean (SD)**   **Statistics for group comparison**
  ----------------------------------------------------------- ---------------------------------- ------------------------------------ -------------------------------------------------------------------------------------
  **Self-reported measures**                                                                                                          
  Pain intensity (VAS) (range 0--10)                          5.5 (2.4)                          0.2 (0.5)                            *F*~(1,26)~ = 64.39, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.71, 95% CI = 3.9, 6.7
  Pain-related fear (PHODA) (range 0--100, cutoff score 38)   55.0 (23.9)                        2.3 (3.5)                            *F*~(1,26)~ = 66.84, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.72, 95% CI = 39.5, 66.0
  Fear of movement (TSK) (range 17--68)                       40.9 (9.0)                         27.4 (4.8)                           *F*~(1,26)~ = 26.33, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.48, 95% CI = 7.8, 19.0
  Pain catastrophizing (PCS) (range 0--52, cutoff score 21)   24.2 (14.2)                        3.6 (3.7)                            *F*~(1,26)~ = 27.71, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.52, 95% CI = 12.5, 28.6
  Pain disability (PDI) (range 0--70)                         39.6 (15.9)                        1.9 (5.1)                            *F*~(1,26)~ = 67.04, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.73, 95% CI = 28.3, 47.3
  Perceived activity decline (PAD) (range 0--20)              12.1 (7.4)                         0.1 (0.5)                            *F*~(1,26)~ = 36.53, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.58, 95% CI = 8.0, 16.1
  Physical activity (PARS) (range 0--100)                     35.6 (6.7)                         45.4 (4.6)                           *F*~(1,26)~ = 19.51, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.43, 95% CI = --13.8, --5.0
  Trait anxiety (STAI-Y2) (range 20--80)                      42.6 (10.5)                        31.4 (5.3)                           *F*~(1,26)~ = 21.02, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.46, 95% CI = 8.2, 21.5
  Trait fear of pain (FPQ) (range 0--150)                     47.6 (10.4)                        55.8 (15.2)                          *F*~(1,26)~ = 2.71, *p* = 0.11, η*~*p*~*^2^ = 0.10, 95% CI = --18.5, 2.1
  **Performance tasks**                                                                                                               
  Two-min walking test (distance in meters)                   148.1 (48.4)                       236.9 (28.3)                         *F*~(1,25)~ = 34.53, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.58, 95% CI = --119.9, --57.7
  Stair case walking (average time per step in seconds)       1.52 (0.13)                        0.62 (0.04)                          *F*~(1,~ ~25)~ = 19.32, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.45, 95% CI = 0.48, 1.33

∗∗

Survives Bonferroni correction for multiple comparison (alpha = 0.05/11 = 0.0045); size; 95% CI = 95% confidence interval of the difference (patients -- controls).

### Patients Report More Fear for MOVEMENT Pictures Pre-EXP

The in-scanner fear ratings for MOVEMENT pictures showed a significant Group effect \[*F*~(1,26)~ = 188.15, *p* \< 0.001, η*~*p*~*^2^ = 0.88, 95% CI = 5.6, 7.5\], where patients reported higher fear levels compared to controls ([Figure 2](#F2){ref-type="fig"} and [Supplementary Figure S1](#DS1){ref-type="supplementary-material"} for fear ratings for all Picture Categories). Also, for patients, fear ratings were significantly and strongly correlated with pain-related fear as assessed using the PHODA (*r* = 0.64, *p* = 0.01) ([Figure 2](#F2){ref-type="fig"}).

![**(A)** Fear ratings for the MOVEMENT pictures. Presented are means and standard errors for each group. Horizontal lines and asterisks indicate significant effects (^∗^*p* \< 0.05). **(B)** Correlation between fear ratings for MOVEMENT pictures and pain-related fear as assessed using the PHODA.](fnins-13-00970-g002){#F2}

### Patients Show Increased BOLD Activation to MOVEMENT Pictures Pre-EXP

[Figure 3](#F3){ref-type="fig"} shows activation maps for the MOVEMENT pictures, per Group (see [Supplementary Figure S2](#DS1){ref-type="supplementary-material"} for activation maps of all Picture Categories). Overall, the MOVEMENT pictures elicited activation in a similar network in patients and controls.

![Activation maps for the MOVEMENT Picture Category at pre-EXP, per group. Statistical maps are presented showing the neural activation of the MOVEMENT category relative to baseline for **(A)** Patients with cLBP, and **(B)** Pain-free volunteers, **(C)** Group differences in MOVEMENT condition. Cluster-level correction using *p* \< 0.001 as initial threshold. CDT, cluster-defining threshold. lPFC, lateral prefrontal cortex; mPFC, medial prefrontal cortex; MCC, mid-cingulate cortex.](fnins-13-00970-g003){#F3}

The whole-brain analysis showed a significant group difference in the right posterior insula (MNI *x* = 33, *y* = −10, *z* = 10, *k* cluster size = 206 mm^3^), with patients showed increased BOLD activation compared to controls ([Figures 3](#F3){ref-type="fig"}, [4A](#F3){ref-type="fig"}). The masked analyses in the pre-defined ROIs additionally showed a difference in mPFC (MNI *x* = 0, *y* = 41, *z* = −11, *k* = 4 mm^3^), with patients showing increased BOLD deactivation compared to controls ([Figure 4A](#F4){ref-type="fig"}, [Supplementary Figure S2](#DS1){ref-type="supplementary-material"}, and [Supplementary Tables S1](#DS1){ref-type="supplementary-material"}, [S2](#DS1){ref-type="supplementary-material"}).

![**(A)** Left: average beta values and standard errors for the MOVEMENT vs. baseline contrast for each group at pre-EXP, extracted from the two areas showing group differences. Right: Depiction of the location of the identified clusters. **(B)** Correlations between the posterior insula activation (beta value) and pain-related variables (self-reported and performance tasks). Note that the trendlines and magnitude of the correlations are shown for both the whole group (black) as well as the patient group only (red). mPFC, medial prefrontal cortex; PDI, pain disability index.](fnins-13-00970-g004){#F4}

### Patients' Neural Activation to MOVEMENT Pictures Shows Specific Correlation to Pain-Related Outcomes

Correlation analyses were performed using betas extracted from the right posterior insula and mPFC (i.e., averaged across all voxels in the cluster). When investigating the entire sample, both the activation in the posterior insula and mPFC was correlated to pain intensity and pain-related fear. Activation in the posterior insula was furthermore correlated to pain catastrophizing, pain disability, and both performance tests ([Table 4](#T4){ref-type="table"}). When zooming into the patient group, activation during MOVEMENT pictures in the posterior insula was positively correlated with pain-related fear, pain disability and both performance tasks while activation in mPFC did not correlate with any of the variables ([Table 4](#T4){ref-type="table"}). For the posterior insula, correlations reflected that increased neural activation was related to increased levels of fear, disability and worse performance ([Figure 4B](#F4){ref-type="fig"}). For the mPFC, the correlations were negative and reflected that decreased neural activation was related to increased levels of fear.

###### 

Correlations at pre-EXP between pain-related variables and activation in the regions displaying a group difference.

                                  **Right posterior insula**   **mPFC**                
  ------------------------------- ---------------------------- ----------- ----------- --------
  Pain-related fear (PHODA)       0.69^∗∗^                     0.55^∗^     --0.43^∗^   --0.23
  Fear of movement (TSK)          0.53^∗∗^                     0.40        --0.39^∗^   --0.14
  Pain catastrophizing (PCS)      0.51^∗∗^                     0.27        --0.23      --0.03
  Pain disability (PDI)           0.67^∗∗^                     0.58^∗^     --0.38      --0.13
  Pain intensity (VAS)            0.56^∗∗^                     0.23        --0.48^∗^   --0.36
  Walking performance             --0.71^∗∗^                   --0.68^∗^   0.31        0.25
  Staircase walking performance   0.73^∗∗^                     0.71^∗^     --0.32      --0.20
  Trait fear of pain (FPQ)        --0.33                       0.14        0.33        0.39
  Trait anxiety (STAI-Y2)         0.48^∗^                      0.36        --0.34      --0.14

∗∗

p \< 0.005 (Bonforroni correction for multiple comparison = 0.05/9 = 0.0055),

∗

p \< 0.05, whole group = patients and controls together n = 28, patients only n = 14.

Effects of Exposure *in vivo* Treatment
---------------------------------------

### Patients Show Improvements in Fear and Functioning After EXP Treatment

#### Pre- to post- to FU-EXP changes in patients

Patients showed main effects of Time for pain-related fear, pain-related disability, perceived activity decline, and the performance tests ([Table 5](#T5){ref-type="table"}). There were no main effects for pain intensity, pain catastrophizing and self-reported physical activity, although these measures generally showed a decrease, and showed clinically relevant reductions (defined as reduction of 30% or more compared to baseline) in 60, 60, and 40% of patients in these domains, respectively, from pre- to post-EXP ([Table 5](#T5){ref-type="table"}).

###### 

EXP-induced changes in self-reported measures and performance tasks in the patient group.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                             **Pre- to post-EXP change mean (SE)**   **Pre- to FU-EXP change mean (SE)**   **Stats main effect Session**                                      ***Post hoc* comparisons**        **\> 30% reduction n: Pre- to post n: Pre- to FU**
  ---------------------------------------------------------- --------------------------------------- ------------------------------------- ------------------------------------------------------------------ --------------------------------- ----------------------------------------------------
  **Self-reported measures**                                                                                                                                                                                                                    

  Pain intensity (VAS, range 0--10)                           --1.4 (0.79)                            --2.0 (0.88)                         *F*~2.0,~ ~15.7~ = 3.12, *p* = 0.07, η*~*p*~*^2^ = 0.28            n.a.                              6/10\
                                                                                                                                                                                                                                                5/9

  Pain-related fear (PHODA; range 0--100, cutoff score 38)   --40.7 (5.6)                            --37.3 (5.4)                          *F*~(1.4,~ ~10.0)~ = 44.24, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.86   Post- \< Pre-EXP FU- \< Pre-EXP   9/10\
                                                                                                                                                                                                                                                8/9

  Fear of movement (TSK; range 17--68)                       --12.2 (2.6)                            --9.2 (3.6)                           *F*~(1.8,~ ~14.2)~ = 8.49, *p* = 0.005^∗∗^, η*~*p*~*^2^ = 0.52     Post- \< Pre-EXP                  4/10\
                                                                                                                                                                                                                                                4/9

  Pain catastrophizing (PCS; range 0--52, cutoff score 21)   --11.7 (5.5)                            --11.2 (5.7)                          *F*~(1.1,~ ~8.5)~ = 4.05, *p* = 0.08, η*~*p*~*^2^ = 0.34           n.a.                              6/10\
                                                                                                                                                                                                                                                4/9

  Pain disability (PDI; range 0--70)                         --27.7 (4.2)                            --25.6 (5.6)                          *F*~(1.3,~ ~10.5)~ = 24.84, *p* \< 0.001^∗∗^, η*~*p*~*^2^ = 0.76   Post- \< Pre-EXP FU- \< Pre-EXP   10/10\
                                                                                                                                                                                                                                                7/9

  Perceived activity decline (PAD; range 0--20)              --6.9 (1.7)                             --6.8 (2.3)                           *F*~(1.7,~ ~12.0)~ = 8.13, *p* = 0.007, η*~*p*~*^2^ = 0.54         Post- \< Pre-EXP                  7/10\
                                                                                                                                                                                                                                                6/8

  Physical activity (PARS; range 0--100)                     --8.0 (3.3)                             --4.4 (4.8)                           *F*~(1.6,~ ~13.0)~ = 2.05, *p* = 0.17, η*~*p*~*^2^ = 0.20          n.a.                              4/10\
                                                                                                                                                                                                                                                3/9

  **Performance tasks**                                                                                                                                                                                                                         

  Two-min walking test (distance in meter)                   42.9 (8.7)                              44.5 (13.6)                           *F*~(1.2,~ ~7.1)~ = 12.42, *p* = 0.008, η*~*p*~*^2^ = 0.67         Post- \< Pre-EXP FU- \< Pre-EXP   n.a.

  Stair case walking (average time per step in seconds)       0.57 (0.12)                            0.53 (0.13)                           *F*~(1.1,~ ~5.3)~ = 17.82, *p* = 0.007, η*~*p*~*^2^ = 0.78         Post- \< Pre-EXP FU- \< Pre-EXP   n.a.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

∗∗

Survives Bonferroni correction for multiple comparison (alpha = 0.05/9 = 0.0055), n.a., not applicable.

#### Pre- to post changes in controls

Controls did not show any effects of Time (all *p*'s \> 0.05).

#### Group effects post-EXP

Post-EXP, groups did not differ anymore in fear of movement, pain catastrophizing, self-reported physical activity, and staircase walking. Patients still reported higher pain intensity and pain-related disability compared to controls, and performed significantly worse on the 2 min walking test ([Table 6](#T6){ref-type="table"}).

###### 

Self-reported measures and performance tasks post-EXP.

  ------------------------------------------------------------------------------------------------------------------------------------------------
                                                          **Post-EXP**   **FU-EXP**                                                 
  ------------------------------------------------------- -------------- -------------- ------------------------------------------- --------------
  **Self-reported measures**                                                                                                        

  Pain intensity (VAS)                                    3.2 (2.9)      0.2 (0.3)      *F*~(1,~ ~17)~ = 9.91, *p* = 0.006,\        2.8 (2.9)
                                                                                        η*~*p*~*^2^ = 0.37, 95% CI = 1.0, 5.1       

  Pain-related fear (PHODA)                               10.1 (16.2)    n.a.^+^        n.a.                                        16.0 (19.4)

  Fear of movement (TSK)                                  28.9 (7.6)     29.3 (3.7)     *F*~(1,~ ~17)~ = 0.02, *p* = 0.88,\         32.8 (6.4)
                                                                                        η*~*p*~*^2^ = 0.001, 95% CI = -6.3, 5.5     

  Pain catastrophizing (PCS)                              9.0 (9.7)      3.1 (3.3)      *F*~(1,~ ~17)~ = 3.00, *p* = 0.10,\         10.1 (9.6)
                                                                                        η*~*p*~*^2^ = 0.15, 95% CI = -1.3, 13.1     

  Pain disability (PDI)                                   9.4 (6.9)      1.0 (1.7)      *F*~(1,~ ~17)~ = 12.73, *p* = 0.002^∗∗^,\   11.9 (12.9)
                                                                                        η*~*p*~*^2^ = 0.42, 95% CI = 3.4, 13.4      

  Perceived activity decline (PAD)                        3.4 (4.2)      1.1 (3.3)      *F*~(1,~ ~17)~ = 1.69, *p* = 0.21,\         4.3 (4.1)
                                                                                        η*~*p*~*^2^ = 0.09, 95% CI = -1.4, 6.0      

  Physical activity (PARS)                                44.3 (10.9)    46.9 (6.5)     *F*~(1,~ ~17)~ = 0.38, *p* = 0.55,\         41.9 (13.9)
                                                                                        η*~*p*~*^2^ = 0.02, 95% CI = -11.4, 6.3     

  **Performance tasks**                                                                                                             

  Two-min walking test (distance in meters)               201.6 (27.8)   231.4 (29.9)   *F*~(1,~ ~16)~ = 4.79, *p* = 0.04,\         193.9 (23.2)
                                                                                        η*~*p*~*^2^ = 0.23, 95% CI = -58.8, -0.94   

  Stair case walking (average time per step in seconds)   0.81 (0.21)    0.64 (0.14)    *F*~(1,~ ~15)~ = 3.48, *p* = 0.08,\         0.83 (0.26)
                                                                                        η*~*p*~*^2^ = 0.19, 95% CI = -0.02, 0.35    
  ------------------------------------------------------------------------------------------------------------------------------------------------

∗∗

Survives Bonferroni correction for multiple comparison (alpha = 0.05/9 = 0.0055);

\+

Due to a technical error, responses were not recorded for the majority of volunteers, n.a., not applicable; 95% CI, 95% confidence interval of the difference (patients -- controls).

### Patients Report Less Fear for MOVEMENT Pictures After EXP Treatment

#### Pre- to post- to FU-EXP changes in patients

There was a significant effect of Time for fear ratings for the MOVEMENT pictures \[*F*~(1.56,~ ~12.44)~ = 24.76, *p* \< 001, η*~*p*~*^2^ = 0.76\], with a significant decrease in ratings between pre- and post-EXP (*p-corr* \< 0.001, 95% CI = --7.0, --3.2) and between pre- and FU-EXP (*p-corr* = 0.006, 95% CI = --7.2, --1.4), but no difference between post-EXP and FU-EXP (*p-corr* = 0.81, 95% CI = --1.3, 2.9) ([Figure 5](#F5){ref-type="fig"} and [Supplementary Figure S3](#DS1){ref-type="supplementary-material"} ratings across all Picture Categories).

![EXP treatment-induced changes in fear ratings. Presented are the means and standard errors for the MOVEMENT pictures for each group across time. Horizontal lines and asterisks indicate significant effects (^∗^*p* \< 0.05): group effects are shown in black, while simple effects of Session, separate per group are shown in color (red for patients with cLBP; there were no significant Session effects for controls).](fnins-13-00970-g005){#F5}

#### Pre- to post changes in controls

There was no significant effect of Time \[*F*~(1,~ ~9)~ = 0.31, *p* = 0.59, η*~*p*~*^2^ = 0.03\].

#### Group effects post-EXP

There was a significant Time x Group interaction \[*F*~(1,~ ~18)~ = 55.20, *p* \< 0.001, η*~*p*~*^2^ = 0.78\]. Simple effects per time point showed that at post-EXP, there was no longer a Group difference \[*F*~(1,~ ~18)~ = 1.12, *p* = 0.30, η*~*p*~*^2^ = 0.06, 95% CI = --1.9, 0.6\].

### Patients Show a Decrease in BOLD Activation to MOVEMENT Pictures After EXP Treatment

#### Pre- to post- to FU-EXP changes in patients

The effect of Time was investigated in the clusters showing a group difference pre-treatment (extracted betas from right posterior insula and mPFC clusters) as well as in a whole-brain analysis and in the predefined ROI masks.

The posterior insula cluster showed a main effect of Time \[*F*~(1.8,~ ~14.8)~ = 4.06, *p* = 0.04, η*~*p*~*^2^ = 0.34\], explained by a linearly decreasing response to MOVEMENT pictures over Time \[*F*~(1,~ ~8)~ = 7.02, *p* = 0.03, η*~*p*~*^2^ = 0.40\]. The mPFC only showed a marginally significant main effect of Time \[*F*~2.0,~ ~158~ = 3.25, *p* = 0.07, η*~*p*~*^2^ = 0.29\], explained by linearly increasing response to MOVEMENT pictures over Time \[*F*~(1,~ ~8)~ = 8.7878, *p* = 0.02, η*~*p*~*^2^ = 0.41\] (see [Figure 6](#F6){ref-type="fig"}).

![EXP treatment-induced effects in neural activation to MOVEMENT pictures in the posterior insula **(A)** and mPFC **(B)**. Plotted are averaged beta values and standard errors per time point and per group. Purple lines and asterisks indicate the significant linear effects over Time in patients. ^∗^*p* \< 0.05.](fnins-13-00970-g006){#F6}

The whole-brain analyses showed a decrease in right post-central/supramarginal gyrus and pre-central gyrus, and an increase in activity in the precuneus from pre- to post-treatment ([Figure 7](#F7){ref-type="fig"} and [Table 7](#T7){ref-type="table"}). Comparing pre-treatment to 6 months follow-up, the right angular/inferior parietal lobe, right post-central, right middle frontal/dorsolateral PFC, right inferior frontal/ventrolateral PFC as well as left middle frontal gyrus showed a significant decrease in activation. Lastly, from post-treatment to 6 months follow-up, the right posterior cingulate cortex showed an additional decrease in activation. When evaluating the effect of Time in the predefined ROIs, there was a significant decrease from pre- to FU-EXP in the NAc ([Table 7](#T7){ref-type="table"}), but not in the other ROIs.

![Clusters of EXP treatment-induced changes in neural activation to MOVEMENT pictures in patients with cLBP. **(A)** Differences from pre- to post-EXP were observed in precuneus (increase, red) as well as precentral gyrus and postcentral gyrus/supramarginal gyrus (from left to right; both decreases, blue). In the boxes, the extracted betas from the corresponding cluster are presented seperately for pre-, post- and FU-EXP. Significant differences across Sessions are highlighted by an asterisk (*p* \< 0.05). **(B)** Differences from pre- to FU-EXP along with corresponding beta plots. Significant changes were observed in left middle frontal gyrus, right middle frontal/dorsolateral PFC, right inferior frontal/ventrolateral PFC, right postcentral gyrus, and right angular/inferior parietal lobe (from left to right, all decreases, blue). **(C)** Differences from post- to FU-EXP changes along with corresponding beta plots. A significant difference was found in the posterior cingulate cortex (PCC, decrease, blue). Cluster-level correction using *p* \< 0.001 as initial threshold. Presented in the boxes are means and standard errors. CDT, cluster-defining threshold.](fnins-13-00970-g007){#F7}

###### 

EXP-induced changes in neural activation to MOVEMENT pictures.

                                                                                                          **MNI**                
  ----------------------------------------------------------------------------------------- ------------- --------- ------ ----- -----
  **Patients: pre- to post-EXP (whole-brain analysis -- minimum cluster size 202 mm^3^)**                                        
  R postcentral gyrus/inferior parietal lobe                                                Pre \> Post   54        --28   53    285
  R precentral gyrus                                                                        Pre \> Post   42        --1    60    738
  R Precuneus                                                                               Pre \< Post   6         --62   60    436
  **Patients: pre- to FU-EXP**                                                                                                   
  **Whole-brain analysis (minimum cluster size 210 mm^3^)**                                                                      
  R inferior parietal lobe                                                                  Pre \> FU     54        --31   50    495
  R postcentral gyrus                                                                       Pre \> FU     45        --16   47    228
  R middle frontal gyrus/dlPFC                                                              Pre \> FU     42        8      50    586
  R inferior frontal gyrus/vlPFC                                                            Pre \> FU     45        11     13    292
  L middle frontal gyrus                                                                    Pre \> FU     --33      47     22    347
  **Masked region of interest analysis (FDR *q* \< 0.05)**                                                                       
  Nucleus accumbens                                                                         Pre \> FU     --15      17     --5   4
  **Patients: post- to FU-EXP (whole-brain analysis -- minimum cluster size 159 mm^3^)**                                         
  R/L posterior cingulate gyrus                                                             Post \> FU    3         --28   38    208

#### Pre- to post changes in controls.

There were no effects of Time in the posterior insula and mPFC cluster. In controls, the whole-brain analysis revealed a change in two regions that do not overlap with the regions identified in patients ([Supplementary Table S4](#DS1){ref-type="supplementary-material"}). None of the predefined ROIs showed an effect of Time.

### BOLD Activation to MOVEMENT Pictures Does Not Differ Anymore Between Patients and Controls After EXP Treatment

#### Group effects post-EXP

Post-treatment, no group differences were present anymore in the whole-brain analysis (also not when being less conservative with an initial threshold of *p* \< 0.005 for cluster-size thresholding). None of the predefined ROIs showed a group difference post-EXP. In addition, when performing a Group comparison of the extracted betas from these ROIs, no group difference was identified at post-EXP \[posterior insula: *F*~(1,~ ~18)~ = 2.58, *p* = 0.13, η*~*p*~*^2^ = 0.13, 95% CI = −0.38, 0.05; mPFC: *F*~(1,~ ~18)~ = 2.11, *p* = 0.16, η*~*p*~*^2^ = 0.11, 95% CI = −0.12, 0.63\].

### Neural Activation Changes to MOVEMENT Pictures in Patients Correlate With Changes in Fear Ratings (Explorative Analyses)

We explored whether changes in fear ratings for the MOVEMENT pictures from pre- to post-treatment were associated with specific changes in BOLD activation from pre- to post-treatment in patients. We found indications that a decrease in fear ratings from pre- to post-treatment was correlated to an increase of neural activation in the right hippocampus (MNI *x* = 30, *y* = --22, *z* = --17, *k* = 396 mm^3^) and the left temporal pole (MNI *x* = --42, *y* = 14, *z* = --20, *k* = 568 mm^3^) (see [Figure 8](#F8){ref-type="fig"}). When extracting beta values, we found that the increase in BOLD activation in both regions was also related to decreases in pain-related fear from pre- to post-EXP (PHODA; left hippocampus: *r* = --0.82, *p* = 0.003, temporal pole: *r* = --0.89, *p* = 0.001) and to decreases in pain-related disability from pre- to post-EXP (PDI; left hippocampus: *r* = --0.78, *p* = 0.007, temporal pole: *r* = --0.71, *p* = 0.02).

![Explorative analyses: EXP treatment-induced changes in fear correlate with changes in neural responses to pain-related fear. **(A)** Brain regions showing a correlation between change in fear rating and change in neural activation (beta value) from pre- to post-EXP, corresponding to the left temporal pole and the left hippocampus (yellow). The scatterplots present the correlations between the change in neural activation in temporal pole (left) and hippocampus (right) with the proportion of reduction in fear ratings from pre- to post-EXP. ^∗^Note that the correlations were evaluated with and without the outlier (i.e., the individual with the lowest reduction in MOVEMENT fear rating). The outlier was not influential, as the correlations were still highly significant. **(B)** Brain regions showing a correlation between change in fear rating and change in neural activation (beta value) from pre- to FU-EXP, corresponding to the ventromedial prefrontal cortex (vmPFC)/anterior cingulate cortex (ACC) and the posterior cingulate cortex (PCC) (green). The scatterplots present the correlations between the change in neural activation in vmPFC (left) and PCC (right) with the proportion of reduction in fear ratings from pre- to FU-EXP. Cluster-level correction using *p* \< 0.005 as initial cluster-defining threshold (CDT).](fnins-13-00970-g008){#F8}

The decrease in fear ratings from pre- to FU-EXP was furthermore related to an increase in right PCC (MNI *x* = 6, *y* = --55, *z* = 10, *k* = 407 mm^3^) and mPFC (MNI *x* = 0, *y* = 47, *z* = --5, *k* = 564 mm^3^). The right PCC betas additionally showed significant correlations to decreases in pain-related fear from pre- to FU-EXP (PHODA; *r* = --0.88, *p* = 0.002). [Figure 8](#F8){ref-type="fig"} shows these relations in more detail.

None of these clusters showed a main effect of Time \[hippocampus: *F*~(2.0,~ ~15.7)~ = 0.35, *p* = 0.71, η*~*p*~*^2^ = 0.04; temporal pole: *F*~(1.6,~ ~12.5)~ = 0.03, *p* = 0.94, η*~*p*~*^2^ = 0.004; PCC: *F*~(1.7,~ ~13.9)~ = 2.87, *p* = 0.10, η*~*p*~*^2^ = 0.26; mPFC: *F*~(1.5,~ ~12.1)~ = 0.29, *p* = 0.69, η*~*p*~*^2^ = 0.04\].

Discussion
==========

We provide the first evidence that clinical improvements following EXP in patients with cLBP are mirrored by changes in the neural circuitry for pain-related fear, the main target of EXP. Pre-treatment, we identified group differences in in-scanner fear ratings and neural responses to pictures of back-specific movements: compared to pain-free controls, patients with cLBP showed increased activation in the right posterior insula and increased deactivation in mPFC. Post-treatment, group differences were no longer present, and the process of change continued in patients at 6 months follow-up. Apart from general changes across treatment in lateral PFC, PCC, precuneus, NAc, and pre- and post-central gyrus, patients showed neural changes specifically related to changes in in-scanner fear ratings in the temporal pole, mPFC, PCC, and hippocampus. Pain-free volunteers did not show this, indicating that these changes cannot be attributed to general habituation effects. Hence, we provide evidence for treatment-induced neural changes in chronic pain that are specific to and correlate with improvements in self-reported fear.

Replicating the Positive Clinical Effects of EXP
------------------------------------------------

As expected, after EXP treatment, pain-related fear and disability significantly decreased while the patient's performance (i.e., walking and stair case walking) improved significantly. Changes were maintained, or in some cases even more pronounced, 6 months after the end of treatment. We did not observe a significant effect of EXP on pain intensity, which is not uncommon nor unexpected. EXP focuses on reducing pain-related disabilities and reducing pain intensity is no explicit aim. Some studies, however, have observed significant improvements in pain intensity on a group level ([@B17]; [@B28]), and also in the current study we observed improvements in some patients (i.e., clinically meaningful reduction in 60% of the patients). In future studies, it would be interesting to examine why some people respond with a reduction in pain intensity, while others do not. The lack of effect on pain catastrophizing is surprising though and not expected, given previous studies (see e.g., [@B46]; [@B17]; [@B48]) and the focus of EXP on disconfirming negative beliefs ([@B89]; [@B18]). Also for pain catastrophizing, however, we did observe a reduction on average as well as clinically meaningful reductions in 60% of patients (pre to post-EXP), suggesting that there was an effect which did not reach significance due to a relatively small sample size.

Pre-treatment Group Differences in Fear Circuitry
-------------------------------------------------

We identified two brain regions showing a group difference in neural responses to pain-related fear. In the right posterior insula and mPFC, patients with cLBP showed altered neural activation compared to controls in response to our fear-evoking task. Focusing on pain-related fear, previous studies have demonstrated increased activation in the insula, as well as in other in regions including the ACC, superior parietal cortex, amygdala, orbitofrontal cortex, and striatum in patients compared to controls ([@B77]; [@B54]). A potential explanation for the difference in extent of findings is our more stringent statistical thresholding ([@B93]) (i.e., with less stringent parameters, additional brain regions showed group differences; and when taking the picture categories together, a multitude of regions differed across groups, including ACC, superior parietal cortex and striatum, see [Supplementary Information](#DS1){ref-type="supplementary-material"}). Previous work related activation in insula, amygdala and several other regions to the amount of pain-related fear ([@B54]). Here, we extend these findings by showing that increased posterior insula activation is furthermore related to pain-related disability and actual physical performance (i.e., walking). In addition, its response was parametrically modulated by in-scanner fear ratings ([Supplementary Information](#DS1){ref-type="supplementary-material"}), further strengthening its specific involvement in pain-related fear. The insula is a core region involved in fear learning ([@B67]; [@B25], [@B24]), although loci are typically more anterior. The posterior insula, in contrast, has been associated with interoceptive integration ([@B12]), sensory aspects of pain/nociception ([@B26]; [@B91]; [@B66]), and experimental rather than clinical pain ([@B65]). This fits with abundant connections between posterior insula and somatosensory cortex (SI/SII; [@B92]). Our finding that posterior insula activation was modulated by fear ratings, however, indicates additional involvement in pain-related fear, possibly due to a top-down modulatory effect of fear on this more sensory region.

The mPFC, and more specifically its ventromedial part (vmPFC), is also a core region involved in fear acquisition and extinction ([@B67]), and general emotion regulation ([@B73]; [@B32]). mPFC involvement in pain and chronic pain is furthermore extensive ([@B61]). Our finding that mPFC showed a decreased (i.e., increased deactivation) response to fear-evoking stimuli in patients could point toward altered inhibitory control, and reduced ability to modulate or self-regulate pain ([@B80]; [@B94]; [@B61]). To our surprise, amygdala activation to feared stimuli was not different across groups. Previous studies consistently reported the amygdala as a brain area of interest in (chronic) pain (see e.g., [@B70]) and fear or more generally threat ([@B44]). It may be that functional connectivity rather than neural activation distinguishes patients from controls. This will have to be explored in further analyses.

Patient-Specific Neural Changes Across Treatment
------------------------------------------------

The increased posterior insula response to our stimuli in patients pre-treatment was reduced over the course of EXP, as was the increased mPFC deactivation. Importantly, we no longer observed group differences post-treatment. This is in accordance with normalizations observed in fear ratings as well as in most clinical measures. Treatment effects were still present or even increased at 6 months follow-up, suggesting generalization to daily life. This is in accordance with a recent RCT in complex regional pain syndrome, where EXP effect sizes were larger at 6 months follow up compared to post-treatment ([@B17]).

Furthermore, several brain regions showed changes in neural responses across treatment, including pre- and post-central gyrus/supramarginal gyrus, precuneus, lateral PFC, and NAc. In *pre- and post-central gyrus/supramarginal gyrus*, we observed decreases from pre- to post-EXP and from pre-EXP to follow-up. Recruitment of these areas associated with motor control, sensory properties of somatosensory stimuli ([@B62]), as well as sensorimotor imagery ([@B52]; [@B35]) was expected, as participants were imagining performing movements and activities depicted in the stimuli. Functional changes in sensorimotor regions have previously been identified in chronic pain ([@B21]; [@B40]). The changes over time we observed may reflect normalizations in sensorimotor neurocircuitry, and along similar lines it may also reflect changes in physical performance that go alongside with EXP, as an indirect result of reducing pain-related fear. The *precuneus*, on the other hand, showed increased activation over the course of treatment. The precuneus is part of the default-mode network (DMN), involved in interoception, mentalizing, integrating information more than processing it ([@B10]). Its activation has been negatively correlated to pain sensitivity, without contributing to the actual neural representation of pain ([@B29]), the direction of which is in line with our findings. Interestingly, in fibromyalgia, abnormalities in connectivity between the insula (including posterior part) and the DMN have been observed ([@B60]), and changes herein and in posterior insula glutamate levels have been observed following treatment-induced pain reductions ([@B59]; [@B31]). *Two prefrontal clusters*, one in dorsal, one in ventral lateral PFC and a subcortical *NAc* cluster showed decreased activation from pre-EXP to 6 months follow-up. The NAc is a major reward center of the brain, and has been implicated in the regulation of pain ([@B94]) and in the chronification of pain ([@B2]; [@B5]). It is also associated with experiencing pain in the chronic phase ([@B34]), representing its motivational value. Our finding indicates that EXP also induces changes in the motivational component of pain and associated pain-related cues (e.g., reduced motivational salience of the back-related pictures following EXP). The dlPFC is also involved in the regulation of pain ([@B49]; [@B69]), and abnormally increased activation has been observed in chronic pain ([@B69]). Interestingly, following treatment, activation in the dlPFC during a cognitively demanding task as well as increases in cortical thickness were normalized ([@B68]). In contrast, the vlPFC has been associated with affective/motivational processing, and control of goal-directed behavior ([@B78]; [@B64]). It has extensive connections with orbitofrontal cortex and subcortical areas such as the amygdala, and also interacts with motor regions to orient attention ([@B11]). Neural changes in this region to pain stimuli have been observed following CBT in fibromyalgia, but in opposite directions ([@B37]). Importantly, additional analyses show that such changes did not occur in controls ([Supplementary Information](#DS1){ref-type="supplementary-material"}), suggesting that these time-dependent changes are not due to general habituation effects, but instead specific to the patient group and likely attributable to treatment.

Neural Changes Specific to Reductions in Pain-Related Fear Ratings
------------------------------------------------------------------

We explored whether fear reduction was associated with specific changes in neural activation to our stimuli. In these explorative analyses, we found indications that pre- to post-EXP decreases in fear ratings were associated with neural activation increases in right hippocampus and left temporal pole. Decreased ratings from pre-EXP to follow-up were associated with increases in the mPFC and PCC. The mPFC, PCC, and hippocampus are associated with fear extinction ([@B67]). Reduced hippocampal volumes and abnormal hippocampal connectivity have been reported in chronic pain ([@B58], [@B57]). Treatment-induced increases in mPFC neural activation in relation to decreases in fear is in agreement with increased inhibitory control occurring during fear extinction. Cautiously, our findings suggest that extinction during EXP may reflect similar working mechanisms as observed during experimental extinction studies. Noted, the initial cluster-defining statistical threshold (CDT) for cluster-size thresholding was slightly less conservative (*p* \< 0.005), which we consider fair given the additional constraints of the analysis. Also note that these regions did not show main effects across treatment, suggesting individual rather than group-level differences. Future analyses will have to investigate whether there are functional connectivity alterations between mPFC and amygdala, which would be the hypothesized mechanism of extinction ([@B63]; but also see [@B23]; [@B56]).

Limitations and Future Considerations
-------------------------------------

Our findings should be interpreted in light of its limitations. First, there was no control treatment, hence we cannot infer that neural changes are specific to EXP. Though, our pain-free control group did control for effects of practice and time. And as we focused on pain-related fear -the main target of EXP-, related findings to within-session fear ratings as well as to clinical assessments of pain-related outcomes, this adds to the specificity of our findings. Second, the focus here is on the MOVEMENT category, because it is most relevant for our patient group, but also for simplicity reasons. Not all findings were specific to this category (e.g., the other two categories also showed pre-EXP posterior insula differences). However, most importantly, time-dependent changes in these regions were specific to this category ([Supplementary Information](#DS1){ref-type="supplementary-material"}). Finally, the relatively small sample size may have comprimised our statistical power, and motivated us to focus on the whole-brain correlation analysis only (i.e., no other correlations with changes over time), limiting the generalizability of our findings. Several participants could not be included in our analyses or were lost to follow-up, partly because our study was conducted amidst clinical standard care (e.g., the patient and/or clinical team decided not to start EXP), and partly due to the challenges of conducting MRI research in clinical pain populations. Despite that, we show strong data of group differences as well as changes across time, all surviving stringent statistical testing. Larger samples will be needed to reproduce the current findings, and to extend to models predicting treatment responses.

Conclusion
==========

We show the first evidence that clinical improvements in chronic pain following EXP treatment are mirrored by changes in pain-related fear neural circuitry. Group differences identified prior to treatment were no longer present after treatment. Time-dependent effects in patients continued up to 6 months after the end of EXP, and involved regions implicated in cognitive/affective, motivational as well as sensory aspects related to pain. This suggests that the effects of EXP are long-term and go above and beyond modulating fear circuitry. Lastly, explorative analyses found indications that brain regions implicated in fear extinction -including the hippocampus, PCC and mPFC- changed their neural response proportionate to the change in self-reported fear, suggesting that extinction during EXP may reflect similar working mechanisms as extinction in experimental settings. Taken together, our findings show that neural circuitry for pain-related fear is modulated by EXP, and that changes are associated with self-reported improvements in pain-related fear.

Data Availability
=================

The datasets generated for this study are available on reasonable request to the corresponding author.

Ethics Statement
================

This study involving human participants was reviewed and approved by the Medical Ethical Committee of Maastricht University Hospital/Maastricht University (MUMC+/UM). All participants provided their written informed consent to participate in this study.

Author Contributions
====================

IT, JJ, MG, JV, RS, and AK contributed to the conception and design of the study. IT and AK acquired the data and contributed to the data analysis plan. IT performed the data analysis and wrote the manuscript. All authors contributed to the manuscript, and read and approved the final version.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by a grant from the Health Foundation Limburg (Stichting Sint Annadal, Maastricht), Board of Directors of Maastricht University Medical Center (MUMC+), and Esperance Foundation (Stichting Esperance).

We would like to thank all participants for their time and effort. We would also like to thank the staff of the Department of Rehabilitation Medicine, and in particular Daniëlle Wijnants, and Department of Radiology of MUMC+/Adelante for their help in (coordinating) the study visits and support with scanning, respectively, and Emma Biggs, Judith Eck, and Johan Vlaeyen for fruitful discussions.

<http://www.qualtrics.com>

Also, participants were asked not to change anything in their medication use on the day of the MRI, and all confirmed they did not take less or more medication than usual. See [Supplementary Table S3](#DS1){ref-type="supplementary-material"} for an overview of the patients' medication use.

Supplementary Material
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnins.2019.00970/full#supplementary-material>
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